B1-05: Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): final results of a multi-center, double-blind, randomized, placebo-controlled phase II study  by Vansteenkiste, Johan et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS334
tumors. Vascular endothelial growth factor (VEGF) induces vascular 
permeability and plays a major role in vasculogenesis, angiogenesis, 
and endothelial integrity and survival. Besides VEGF-, other proangio-
genic factors such as platelet derived- (PDGF), and ﬁbroblast growth 
factor (FGF) with their receptors compose critical cellular pathways 
controlling lung cancer vascularization, growth and progression. BIBF 
1120 is an oral potent triple angiokinase inhibitor targeting VEGFR, 
PDGFR, FGFR kinases.
Methods: In this double blind multi-centre trial, patients with an 
ECOG score of 0-2 with locally advanced or metastatic (stage IIIB/IV) 
relapsed NSCLC after failure of ﬁrst or second line chemotherapy were 
randomly assigned to daily treatment with 2x250 mg or 2x150 mg of 
BIBF 1120 until progression. In the event of dose limiting toxicity, a 
single dose reduction to open label treatment with 2x150 or 2x100 mg 
of BIBF 1120 was allowed. Patients with stable brain metastases or 
squamous cell carcinoma were not excluded. The primary endpoints 
were progression free survival (PFS) and objective tumour response 
according to RECIST (determined every 6 weeks).
Results: A total of 74 patients were enrolled and 73 patients treated 
with BIBF 1120 (61% males, median age: 64 years, range 36-80). The 
most common histology was adenocarcinoma (55%), followed by squa-
mous cell carcinoma (23%). The median PFS of all patients (n= 73) 
was 1.6 months without signiﬁcant difference between both treatment 
arms. The stable disease rate was 48%. One conﬁrmed partial response 
was observed. 
Patients with an ECOG performance status of 0 or 1 (n= 57) had a me-
dian PFS of 2.9 months and a three- and ﬁve months PFS rate of 46% 
and 31%, without any difference between both treatment arms. The 
stable disease rate in this group of patients was 59% and the median 
overall survival was 144 days.
Patients treated with 2x250 mg per day had more CTCAE Grade 3 
and 4 toxicities as compared to patients treated with 2x150 mg (27% 
versus 2.8%, p=0.006, two-sided Fisher-test). The most frequent 
adverse events irrespective of relatedness observed in 73 patients were 
of CTCAE Grade 1 or 2 and included nausea (41%), diarrhoea (41%), 
vomiting (33%), fatigue (29%), and abdominal pain (22%). Grade 3 
and 4 toxicities included nausea (8%), diarrhoea (7%), vomiting (4%), 
abdominal pain (4%) and AST and/or ALT elevations (5.4%) which 
were fully reversible.
Conclusions: These results suggest that continuous treatment with 
BIBF 1120 is safe and well tolerated, and showed promising efﬁcacy in 
ECOG 0-1 patients. A considerably high rate of disease control could 
be observed in this study.
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Background: DN-101 is a high dose oral formulation of calcitriol, the 
most potent ligand of vitamin D receptor. Calcitriol has various anti-
neoplastic effects on malignant cells and increases activity of cytotoxic 
agents, including taxanes. DN-101 in combination with docetaxel 
increased survival in a phase 2 study in androgen-independent prostate 
cancer and ASCENT 2, a phase 3 conﬁrmatory study is underway. The 
objective of the study was to determine the maximum tolerated dose, 
response rate (ORR), progression-free survival (PFS), and overall 
survival (OS) of DN-101 in combination with docetaxel in advanced 
NSCLC patients (pts). 
Methods: Eligible pts had Stage IIIB or IV NSCLC that progressed 
on or after platinum-based chemotherapy, ECOG ≤ 1, and measurable 
disease by RECIST criteria. DN-101 was administered on day 1 in 
doses of 45 (n=5), 75 (n=4), 135 (n=3), or 180 µg (n=53) in the q21d 
group, or 180 µg on day 1, followed by 45 (n=5), 90 (n=4), or 180 µg 
(n=12) on days 8 and 15 in the q7d group. Docetaxel (75 mg/m2 BSA) 
was given on day 2 q21d for all pts. 
Results: A total of 86 pts were treated. No unexpected toxicities were 
reported with DN-101. Grade (G3/4) toxicities and fatal adverse events 
(AEs) were consistent with the reported toxicity of docetaxel alone. 
Stomatitis (0% in q7d, 9% in q21d) and G3/4 asthenia and fatigue 
(5% in q7d, 14% in q21d) were less frequent on DN-101 compared to 
published reports on docetaxel. No pt on DN-101 q21d developed hy-
percalcemia while 2 pt on DN-101 q7d (180 µg cohort) developed G3/4 
hypercalcemia. Three fatal AEs included 2 on DN-101 q21d (1 lung 
inﬁltration, 1 pneumonitis) and 1 on DN-101 q7d (intestinal perfora-
tion). The ORR was 5.9% (CI 0.1%, 28.7%) and 6.6% (1.8%, 15.9%), 
median PFS 14.1 (6.0, 20.0) and 11.6 (8.4, 17.4) weeks, median OS 
8.8 (7.1, NA) and 6.9 (5.5, 9.7) months, and 1 year survival rate 40% 
(15.2%, 64.8%) and 31% (18.9%, 42.2%) for the q7d and q21d group, 
respectively. 
Conclusion: DN-101 in combination with docetaxel is well-tolerated 
in advanced NSCLC. The observation of improved PFS, OS, and 1 
year survival rate with weekly DN 101 supports further investigation, 
as does the appearance of ameliorated docetaxel-induced toxicity when 
combined with DN-101. 
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Background: NSCLC is associated with poor outcome: even after 
complete surgical resection, about half of the patients with stage IB or 
II NSCLC relapse and die within 5 years. Cisplatin-based adjuvant che-
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motherapy improves overall survival but at the expense of substantial 
toxicity. The MAGE-A3 gene is expressed speciﬁcally in tumor cells 
with no expression in normal cells. Pilot studies evaluating the MAGE-
A3 cancer immunotherapeutic (i.e. MAGE-A3 recombinant protein 
combined with a potent GSK proprietary immunological adjuvant) 
showed a good tolerability and long-lasting clinical objective responses 
in metastatic melanoma. Because MAGE-A3 is signiﬁcantly expressed 
in NSCLC (35% in stages IB or II), post-operative immunization with 
the MAGE-A3 cancer immunotherapeutic may be a tumor-speciﬁc, 
well tolerated, and effective adjuvant therapy.
Methods: Patients with completely resected, MAGE-A3 (+), patho-
logical stage IB or II NSCLC were randomly assigned to postoperative 
intramuscular administrations of MAGE-A3 or placebo (2:1), with 5 
administrations at 3-week intervals, followed by 8 administrations ev-
ery 3 months. Stratiﬁcation factors included stage (IB vs. II), histology 
(squamous carcinoma vs. other), and lymph-node procedure (minimal 
lymph-node sampling vs. radical mediastinal lymphadenectomy). The 
primary endpoint was disease-free interval; secondary endpoints were 
safety, disease-free survival, and overall survival. This Phase II study 
(study ID249553/004/NCT00290355) was designed to detect a clini-
cally relevant hazard ratio with a 10% one-sided α.
Results: 1089 tumor samples were examined, of which 363 expressed 
the MAGE-A3 gene. 182 patients (122 stage IB, 60 stage II) from 59 
centers in 14 European countries were randomized over 2 years. The 
patient characteristics are the following: Median age 63 (45-81); 87% 
male; 65% squamous cell carcinoma; 65% systematic radical medi-
astinal lymphadenectomy. After a median follow-up of 28 months, 67 
recurrences were observed. Group comparisons of disease-free interval, 
disease-free survival, and overall survival gave respectively a hazard 
ratio of 0.74 (95% CI 0.44-1.20, p=0.107), 0.73 (95% CI 0.45-1.16, p = 
0.093) and 0.66 (95% CI 0.36-1.20, p = 0.088) in favor of the MAGE-
A3 group. Overall, treatment was well tolerated. Subset analysis sug-
gests that systematic radical mediastinal lymphadenectomy may have a 
positive effect on survival.
Conclusions: The ﬁnal analysis of this randomized Phase II study 
shows a positive signal for clinical activity of MAGE-A3 cancer im-
munotherapeutic as adjuvant treatment in completely resected Stage 
IB or II NSCLC. The relative improvement in disease-free interval and 
disease-free survival is 27%. This treatment is well tolerated. Further 
Phase III evaluation in early NSCLC is planned for 2007.
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Background: Bcl-2 protein is a fundamental cause of tumor cell ac-
cumulation and resistance to anticancer therapy. Oblimersen (Genas-
ense®), a Bcl-2 antisense oligonucleotide, selectively targets bcl-2 RNA 
for degradation by RNase H and thus decreases Bcl-2 protein produc-
tion. Oblimersen enhances the activity of anticancer agents (including 
docetaxel) in animal models, including NSCLC. Findings in clinical 
studies conducted in patients with various solid tumors and hemato-
logic malignancies support this effect.
Methods: A multicenter, randomized study of docetaxel versus 
docetaxel plus oblimersen was conducted in patients with NSCLC who 
had received not more than 1 prior exposure to cytotoxic chemotherapy 
and had relapsed after or were refractory to that therapy. Patients were 
≥ 18 years of age and had measurable disease (Stage IIIB or IV) not 
previously irradiated, ECOG performance status ≤ 2, adequate organ 
function, and a life expectancy ≥ 12 weeks. Key exclusion criteria 
were untreated or symptomatic brain metastases, peripheral neu-
ropathy ≥ Grade 2, and prior radiation therapy to ≥ 25% of the bone 
marrow. Patients were stratiﬁed based on 3 factors (response to prior 
chemotherapy, ECOG performance status [0 or 1 versus 2], and prior 
paclitaxel treatment [yes versus no]) and then centrally randomized at 
a 1:1 ratio. Patients received docetaxel 75 mg/m2 on Day 1 by IV infu-
sion or oblimersen 7 mg/kg/d on Days 1 to 7 by continuous IV infusion 
plus docetaxel 75 mg/m2 on Day 5 of each 21-day cycle for up to 8 
cycles. Patients were assessed for response prior to Cycles 3, 5, and 7, 
at completion of treatment, and up to 18 months after randomization. 
Endpoints include time to progression, survival at 6 and 12 months post 
randomization, response rate (complete and partial), response duration, 
and safety.
Results: Of 298 patients randomized, 287 initiated treatment. Among 
all patients randomized, the median age was 63 years, and 61% of 
patients were male. A total of 86% of patients had Stage IV disease; 
94% had metastatic disease; and 91% had an ECOG performance status 
of 0 or 1. Prior radiotherapy was reported for 39% of patients and prior 
paclitaxel therapy for 48%. Grade 4 neutropenia of 23% among all 
treated patients compared favorably with that historically reported with 
docetaxel alone.
Conclusions: The database will be unblinded in Quarter 2, 2007, and 
results presented.
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Background: In two randomized studies, MGd when combined with 
WBRT prolonged time to progression of neurologic endpoints in 
NSCLC patients (pts) with brain metastases (BM). Neurocognitive test-
ing, which has been shown to correlate with clinical outcome in brain 
tumor patients, was performed in both studies. The purpose of this 
analysis was to pool the neurocognitive data from both trials.
